• Product NameMLN9708
• Brief DescriptionInhibitors
• Purification98.79%
• Biological ActivityMLN9708 immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM, less potent to β1 and little activity to β2. Phase 3.
• Target NameProteasome inhibitor
• CAS No. 1201902-80-8
• Calculated MW 517.12
• Formulation C20H23BCl2N2O9
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Other
  SMILES:B1(OC(=O)CC(O1)(CC(=O)O)C(=O)O)[C@H](CC(C)C)NC(=O)CNC(=O)C2=C(C=CC(=C2)Cl)Cl
  Pathways:Proteases/Proteasome; Ubiquitination
  Receptor:20S proteasome; 20S proteasome
  Boling pt:
  Melting pt:
  Solubility:DMSO: 100 mg/mL (193.37 mM)
  Appearance:Faint Yellow Solid
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Kupperman E, et al. Y Res, 2010, 70(5), 1970-80.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting